JP Morgan Maintains Overweight on Enovix, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Bill Peterson maintains an Overweight rating on Enovix (NASDAQ:ENVX) but lowers the price target from $18 to $15.
October 22, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan's analyst Bill Peterson continues to rate Enovix as Overweight, indicating a positive outlook, but has reduced the price target from $18 to $15, suggesting a tempered expectation of growth.
The Overweight rating suggests a positive outlook, but the lowered price target indicates a reduced expectation of growth. This mixed signal may lead to neutral short-term price movement as investors digest the implications.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100